Home
About Us
Introduction
R&D and Production
Platform
Social Responsibility
Products
GLP-1 Side Chains
AEEA
AEEA-AEEA
Boc-AEEA-OH
Fmoc-AEEA-OH
tBuO-C20-Glu-OtBu
tBuO-C20-Glu(OSu)-OtBu
Peptide Intermediates
Fmoc-His-Aib-OH
Fmoc-Ile-Aib-OH
Fmoc-Tyr(tBu)-Aib-OH
Fmoc-Glu(OtBu)-Aib-OH
Fmoc-His(Fmoc)-Aib-OH
Fmoc-His(Fmoc)-Aib-OSu
Tirzepatide Fragments
CAS:2682040-93-1
CAS:3034670-52-2
CAS:2656383-23-0
CAS:2461524-68-3
CAS:2656383-24-1
CAS:2656383-25-2
API & Excipients
Tirzepatide
Semaglutide
Salcaprozate Sodium (SNAC）
Cosmetic Peptides
Oligopeptide-1
NonaPeptide-1
Copper Tripeptide-1
Acetyl Hexapeptide-8
Palmitoyl Tripeptide-1
Decarboxy Carnosine HCl
Active Ingredients
Bisyne<sup>®</sup>
CG HPR
CG Chroman'6<sup>®</sup>
CG Retinol
CG HP100
Adsolue <sup>®</sup> TPGS
News
Events
Industry News
Contact
Search
marketing@congenpharm.com
Peptide oil care reaches new heights: Inactiv nanometer lock-control technology, resists outward flow, solves the problem of active ingredients "not staying"
2024-11-01
Congen Pharma invites you to the 10th National Academic Exchange Conference on Cutting-Edge Technologies for Peptide Drug R&D and Mass Production
2024-10-31
The meteoric rise of semaglutide, a drug that transcends boundaries
Truly effective ingredients | Patented HPR high-stability formula, the path to youthful skin with super vitamin A
2024-09-26
Congen Pharma showcased at CPHI & PMEC Pharmaceutical Industry Exhibition, jointly building a new highland for the pharmaceutical industry in South China and Asia
2024-09-12
Congen Pharma obtains a new invention patent, further improving the stability of Hypervitamin A (HPR)
2024-09-06
